Need professional-grade analysis? Visit stockanalysis.com
$1.85B
6.74
128
N/A
Aurinia Pharmaceuticals Inc (AUPH) trades on United States in USD. The company is classified in the Healthcare sector under the Biotechnology industry. The stock currently trades at $15.82, down 1.43% from the previous close.
Over the past year, AUPH has traded between a low of $7.47 and a high of $16.37. The stock has gained 95.6% over this period. It is currently 111.8% above its 52-week low.
Aurinia Pharmaceuticals Inc has a market capitalization of $1.85B, with a price-to-earnings ratio of 6.74.
Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. It also develops aritinercept, a dual inhibitor of B cell-activating factor and proliferation-inducing ligand for the potential treatment of autoimmune diseases. The company was founded in 1993 and is headquartered in Edmonton, Canada.
Side-by-side comparison against top Healthcare peers.